Therefore, skewing IL-7Rα/PD-1 balance towards PD-1 by either stimulating PD-1/PD-L1 pathway or suppressing IL-7Rα signaling may have therapeutic potential for the treatment of autoimmune diseases, including MS. This evidence concerns the gene IL7R and myeloid sarcoma.